✦ LIBER ✦

Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care?

✍ Scribed by Lankester, Arjan C.; Locatelli, Franco; Bader, Peter; Rettinger, Eva; Egeler, Maarten; Katewa, Satyendra; Pulsipher, Michael A.; Nierkens, Stefan; Schultz, Kirk; Handgretinger, Rupert; Grupp, Stephan A.; Boelens, Jaap Jan; Bollard, Catherine M.

Book ID: 126253869
Publisher: Elsevier Science
Year: 2015
Tongue: English
Weight: 777 KB
Volume: 21
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2014.07.018

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Will T-cell therapy for cancer ever be a

Will T-cell therapy for cancer ever be a standard of care?

✍ Brenner, M K 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 178 KB

Nursing care of the granulocyte donor fo

Nursing care of the granulocyte donor for pediatric stem cell transplant patients

✍ T.J. Stanton; A.L. Marconi; J. Allison; J. Kurtzberg 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 73 KB

Can stereotactic fractionated radiation

Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma

✍ Nam P. Nguyen; Linda Garland; James Welsh; Russ Hamilton; Deirdre Cohen; Vincent 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 149 KB

Antibiotic Prophylaxis Therapy for Pedia

Antibiotic Prophylaxis Therapy for Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT): A Tale of 2 Centers

✍ Schechter, Tal; Gassas, Adam; Klein, Joshua; Doyle, John; Berger, Amanda; Ali, M 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 307 KB

O-251 Weight loss and anaemia are poor p

O-251 Weight loss and anaemia are poor prognostic factors for patients with lung cancer receiving chemotherapy — will modification of these prognostic factors become a new standard of care?

✍ Ross, Paul J.; Waters, Justin S.; Ashley, Sue; Priest, Kathy; Norton, Alison; Ei 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 369 KB

PSY5 Comparing Brentuximab Vedotin Overa

PSY5 Comparing Brentuximab Vedotin Overall Survival Data to Standard of Care in Patients With Relapsed/Refractory Hodgkin Lymphoma (HL) Post-Autologous Stem Cell Transplant (ASCT)

✍ Woods, B.; Thompson, J.; Barcena, L.; Liu, Y.; Huang, H.; Martinez, C. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB